Milestone Scientific Reports Epidural, Intra-Articular Unit Will Present Initial Results of Trials for Instrument

Milestone Scientific Inc.'s (NYSE: MLSS) Epidural & Intra-Articular (IA) Subsidiary today announced that it will host an event on November 20th in Miami for a group of leading anesthesiologists and key opinion leaders in the field where it plans to present the interim results from its COMPASS clinical study for the epidural instrument. Milestone Scientific's Epidural & IA Subsidiary will also issue a press release following the event which will include data reviewed with the anesthesiology and pain management experts. The presentation will share how the CompuFlo® Epidural platform technology impacted the safety of epidural procedures and operational efficiencies, and address the potential for malpractice risk reduction.

Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We look forward to unveiling the initial results of the clinical trials to a group of leading industry experts and the public at large. We believe the epidural instrument has the potential to transform an industry that has been plagued with safety concerns with one of the highest rates of malpractice in medicine. We believe these instruments represents the future of drug delivery."